Aikili is addressing development of an automated and accurate diagnosis available to breast cancer patients who would otherwise have limited access to effective diagnosis. Principals of the firm are structured aorund developing a standalone, AI-powered diagnostic system to enable early cancer detection in low resource settings. System has the potential to transform cancer diagnostics in low- and middle-income countries where cytopathology is a major bottleneck. The effort is also to augment workflows by enabling non-expert healthcare workers rapidly to establish cancer diagnoses and identify molecular subtypes within 1 hour - effectively (in near real time) informing the most appropriate therapeutic choices in collaboration with specialist physicians, as well as reducing patient loss to follow-up (LTF)
